Show simple item record

dc.contributor.authorGarranzo-Asensio, Maria 
dc.contributor.authorSan Segundo-Acosta, Pablo
dc.contributor.authorMartínez-Useros, Javier
dc.contributor.authorMontero-Calle, Ana 
dc.contributor.authorFernández-Aceñero, María Jesús
dc.contributor.authorHäggmark-Månberg, Anna
dc.contributor.authorPelaez-Garcia, Alberto
dc.contributor.authorVillalba, Mayte
dc.contributor.authorRábano, Alberto
dc.contributor.authorNilsson, Peter
dc.contributor.authorBarderas Manchado, Rodrigo
dc.identifier.citationOncotarget. 2018 Jan 24;9(13):10847-10867.es_ES
dc.description.abstractAlzheimer's disease (AD) is the most common form of dementia in developed countries. A better understanding of the events taking place at the molecular level would help to identify novel protein alterations, which might be used in diagnosis or for treatment development. In this study, we have performed the high-throughput analysis of 706 molecules mostly implicated in cell-cell communication and cell signaling processes by using two antibody microarray platforms. We screened three AD pathological groups -each one containing four pooled samples- from Braak stages IV, V and VI, and three control groups from two healthy subjects, five frontotemporal and two vascular dementia patients onto Panorama and L-Series antibody microarrays to identify AD-specific alterations not common to other dementias. Forty altered proteins between control and AD groups were detected, and validated by i) meta-analysis of mRNA alterations, ii) WB, and iii) FISH and IHC using an AD-specific tissue microarray containing 44 samples from AD patients at different Braak stages, and frontotemporal and vascular dementia patients and healthy individuals as controls. We identified altered proteins in AD not common to other dementias like the E3 ubiquitin-protein ligase TOPORS, Layilin and MICB, and validated the association to AD of the previously controverted proteins DDIT3 and the E3 ubiquitin-protein ligase XIAP. These altered proteins constitute interesting targets for further immunological analyses using sera, plasma and CSF to identify AD blood- or cerebrospinal fluid-biomarkers and to perform functional analysis to determine their specific role in AD, and their usefulness as potential therapeutic targets of intervention.es_ES
dc.description.sponsorshipThis work was supported by the Ramón y Cajal funding grant, the SAF2014-53209-R and PI17CIII/00045 grants from the Ministerio de Economía y Competitividad and AESI, respectively, and the ILoveScience crowdfunding platform. R.B. was a fellow of the Ramón y Cajal program of the Ministerio de Economía y Competitividad (Spain). M.G.A. is supported by a contract of the Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI) with the participation of the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid y del Fondo Social Europeo. P.S.A. is supported by a FPU fellowship from the Spanish Ministry of Education, Culture and Sport.es_ES
dc.publisherImpact Journalses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectprotein/antibody microarrayses_ES
dc.titleIdentification of prefrontal cortex protein alterations in Alzheimer's diseasees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderMinisterio de Educación, Cultura y Deporte (España)es_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional